Is Mounjaro the same as Zepbound?

Yes, in the sense that matters most: both are the same molecule, tirzepatide, from the same manufacturer. The difference is the brand name and the medical use. Mounjaro is the prescription brand marketed for type 2 diabetes and Zepbound is the prescription brand marketed for chronic weight management, but the tirzepatide inside each pen is identical.

Is tirzepatide just the generic name for Mounjaro and Zepbound?

Tirzepatide is the compound's name, and Mounjaro and Zepbound are the two brand names for it, so it functions like the shared name behind both brands. It is not a cheaper generic you can buy over the counter, though. The branded products are prescription-only pharmaceuticals, and research-grade tirzepatide sold online is a different, unapproved, unregulated item that is not FDA-approved.

Why does one molecule have two different brand names?

It is a regulatory and marketing convention. A manufacturer can seek approval for the same molecule under separate brand names for separate indications, so tirzepatide became Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The naming reflects the paperwork and the intended use, not any difference in the drug itself.

GLP-1

Mounjaro vs Zepbound vs Tirzepatide: Same Molecule, Two Brands, One Honest Explainer

Q: Is research-grade tirzepatide the same as Mounjaro or Zepbound?

No. They share the molecule, but they are not the same product. Mounjaro and Zepbound are the branded prescription versions of tirzepatide, made to a pharmaceutical standard and dispensed under medical supervision. Research-grade tirzepatide sold for lab use is not those products and is not FDA-approved, and it carries sourcing and contamination risks the branded versions do not.

By MrPepTalks Editorial · Updated 2026-07-08

If you have searched "Mounjaro vs Zepbound vs tirzepatide," you have stumbled onto one of the most common points of confusion in the whole GLP-1 conversation. Here is the short version up front: they are not three different drugs. Mounjaro and Zepbound are two brand names for the exact same molecule, tirzepatide, sold by the same manufacturer for two different medical uses. This guide untangles the naming, explains what the research on tirzepatide actually reports, and separates the branded prescription products from the research-grade tirzepatide you may see marketed online, which is a very different thing.

The one-line decoder: Mounjaro and Zepbound are both tirzepatide

Tirzepatide is the compound. Mounjaro and Zepbound are the two brand names its manufacturer, Eli Lilly, gives it. The molecule inside each pen is identical; what differs is the label on the box and the medical use each brand is marketed for. Both are prescription drugs the FDA regulates as pharmaceuticals, dispensed under medical supervision: Mounjaro is the brand marketed for type 2 diabetes, and Zepbound is the brand marketed for chronic weight management, and both are the same underlying tirzepatide. So when a headline pits "Mounjaro vs Zepbound," it is really comparing two uses of one drug, not two rival compounds. You can read our neutral data sheet on the molecule itself at /peptides/tirzepatide.

What tirzepatide is and how it is thought to work

Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it acts on two gut-hormone pathways at once rather than the single GLP-1 pathway that older drugs target. It is commonly researched for weight and blood-sugar outcomes, and it carries some of the strongest human trial data in its class. Because Mounjaro and Zepbound share this molecule, they share this mechanism completely. The dual-receptor design is the feature most often studied for why tirzepatide behaved the way it did in trials, though how much each receptor contributes in humans is still an active research question rather than a settled fact.

What the research actually reports

The tirzepatide trial program is unusually large for this space. In the SURMOUNT-1 trial, the reported outcome was substantial average body-weight reduction over 72 weeks in adults with obesity, and the SURPASS diabetes trials reported improvements in blood-sugar markers versus comparators. We describe these as what the trials reported, not as a promise about any individual, because a trial average is not a personal outcome and the people in these studies were monitored under a prescription protocol. Our verdict deep-dive walks through the strength and the limits of that evidence at /verdicts/tirzepatide, and our weight-loss overview puts tirzepatide in context alongside the rest of the field at /learn/peptides-for-weight-loss.

The distinction that matters most: brand prescription vs research-grade

This is where the naming confusion becomes a safety issue. The trial data above stands behind Mounjaro and Zepbound, the branded prescription products made to a pharmaceutical standard and dispensed under medical supervision. Research-grade tirzepatide sold "for research use only" online is not those products, is not made to that standard, and is not FDA-approved. Sharing a molecule name does not make a gray-market vial equivalent to a prescription pen: the research-grade supply chain is unregulated, so vials can be underdosed, mislabeled, or contaminated, and no agency checks what is actually inside them. We lay out that brand-versus-research line in detail at /learn/research-peptides-vs-prescription-drugs.

The cons and reported side effects

No version of tirzepatide is consequence-free, and honest disclosure matters here. Across the trials, the most commonly reported side effects were gastrointestinal, including nausea, diarrhea, vomiting, and constipation, most often as doses were increased under supervision. Labeling also carries warnings studied in animals, and the full long-term safety picture continues to be characterized. For research-grade tirzepatide bought outside the prescription channel, those baseline risks are compounded by sourcing risk, because an unregulated vial offers no assurance of identity, purity, or dose. We keep a running summary of reported peptide side effects at /learn/common-peptide-side-effects, and the legal picture, which differs sharply between a prescription and a research vial, at /learn/is-my-peptide-legal-2026.

How tirzepatide sits next to semaglutide and retatrutide

Once you know Mounjaro and Zepbound are one molecule, the more useful comparisons are between different molecules. Semaglutide, the compound behind Ozempic and Wegovy, is a single GLP-1 agonist, so a tirzepatide-versus-semaglutide comparison is a genuine head-to-head of two mechanisms rather than two brand names; we cover it at /compare/tirzepatide-vs-semaglutide, with the semaglutide data sheet at /peptides/semaglutide. Retatrutide, an investigational triple agonist still in trials and not approved, is the next step some researchers are watching; see /compare/retatrutide-vs-tirzepatide and the retatrutide data sheet at /peptides/retatrutide. Those are the apples-to-apples questions the brand names obscure.